ImmunoGen Financials

ImmunoGen Stock Summary

ImmunoGen competes with Madrigal Pharmaceuticals, TG Therapeutics, Terns Pharmaceuticals, Hepion Pharmaceuticals, and Viking Therapeutics. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.

ImmunoGen Key Financial Ratios

ImmunoGen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ImmunoGen's current stock value. Our valuation model uses many indicators to compare ImmunoGen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmunoGen competition to find correlations between indicators driving ImmunoGen's intrinsic value. More Info.ImmunoGen is rated fourth overall in return on equity category among its peers. It is rated third overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmunoGen's earnings, one of the primary drivers of an investment's value.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.